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Purpose: To evaluate doctors’ adherence to Malaysian Clinical Practice Guideline (CPG) 2008 in 
established hypertensive patients with cardiovascular diseases and factors associated with guideline 
adherence and hypertension control in Pulau Pinang Hospital, Malaysia. 
Methods: Prescriptions written by 13 doctors for 320 established hypertensive patients with 
cardiovascular diseases (25 patients per doctor) were noted on first visit. Two hundred and sixty (81%) 
of the enrolled 320 patients (20 patients per doctor) were followed up until the second visit. Blood 
pressure (BP) noted on the second visit was related to the prescription written on the first visit.  
Results: One hundred and ninety one (73.5%) patients received guidelines-compliant 
pharmacotherapy. CPG adherence had statistically significant association with left ventricular 
hypertrophy (LVH) (Ф =-0.241, p < 0.01) and diabetes (Ф =-0.228, p < 0.01). One hundred and fifty four 
(59.2 %) patients were on goal BP. Hypertension control had statistically significant association with 
guidelines compliance (Ф = 0.175, p < 0.01), angiotensin converting enzyme (ACE) inhibitors (Ф = 
0.195, p < 0.01), diabetes (Ф = -0.148, p = 0.017), LVH (Ф = -0.153, p = 0.017) and monotherapy (Ф = -
0.168, p < 0.01).  
Conclusion: Prescribing practices were fairly compliant with guidelines. Doctors poorly adhered to 
guidelines in hypertensive patients with diabetes and LVH. Significantly better hypertension control was 
seen in patients who were on ACE inhibitors and guidelines-adherent therapy. 
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INTRODUCTION 
 
The goal of hypertension therapy and control 
is to reduce morbidity and mortality by 
preventing cardiovascular, cerebrovascular 
and renovascular diseases. Randomized 
control trials have shown that pharmaco-
logical intervention and adequate blood 
pressure control were associated with 20 to 
22 % risk reduction of coronary heart disease 
[1] and 28 to 38 % risk reduction in the 
incidence of stroke [2]. To improve 
hypertension control, various hypertension 
management guidelines have been 
published, disseminated and regularly 
updated. These guidelines provide concise, 
evidence based recommendations to the 
prescribers in order to achieve optimal 
hypertension control [3].  
 
Despite the positive impact of guidelines’ 
implementation on hypertension control [4], 
existing literature suggests that patients with 
hypertension are not being treated according 
to guidelines [5]. Observational studies have 
shown that the health care providers’ 
attitudes, behavior towards hypertension 
management and deviation from the clinical 
practice guidelines account for more than 66 
% of the poor control of hypertension [6]. Just 
like other parts of the world, prevalence and 
poor control of hypertension is alarmingly 
high in Malaysia. In 2004, 40.5 % of 
Malaysians aged ≥ 30 years were suffering 
from hypertension, and only 28.6 % of the 
treated hypertensive patients were on goal 
BP [7]. It was also reported that 138,111 of 
the Malaysian individuals suffered from 
cardiovascular diseases in 2006, resulted in 
the death of 9977 people [8]. No study has 
been conducted in Malaysia to evaluate 
doctors’ compliance with Malaysian clinical 
practice guidelines on management of 
hypertension (CPG 2008) [3] in patients with 
cardiovascular diseases. 
This study was conducted to evaluate 
doctors’ adherence to medication 
recommendations of Malaysian clinical 
practice guidelines on management of 
hypertension (CPG 2008). In addition, this 
study also aimed to evaluate factors 
associated with guidelines adherence and 
hypertension control in established 





This was a cross-study conducted at the 
cardiology outpatient clinic of Pulau Pinang 
Hospital, Malaysia. During the study period, 
all doctors (n=13) practicing at cardiology 
outpatient clinic were enrolled in the study 
and a signed written consent form obtained 
from them. In order to evaluate prescription 
written by each enrolled doctor to a purposive 
sample of 20 patients, a total of 325 
established hypertensive patients with 
cardiovascular comorbidities who had clinical 
encounter with the enrolled doctors (25 
patients per enrolled doctor including drop 
out rate of 25 %) were included in the study. 
The inclusion criteria were: established 
hypertensive patients with cardiovascular 
disease, aged ≥ 18 years and < 80 years, 
clinical encounter with enrolled doctor and 
follow up on next visit at Pulau Pinang 
Hospital. All pregnant hypertensive patients 
and patients who were referred for follow up 
to clinics other than outpatient cardiology 
clinic of Pulau Pinang Hospital were 
excluded.  
 
On 1st visit, a purpose-developed validated 
data collection form was used to collect 
patients’ demographic and clinical data. 
Hypertension diagnosis and other 
comorbidities were based on documentation 
from patients’ medical record. Patients with 
history of angina pectoris, myocardial 
infarction or any diagnosis of coronary artery 
disease were considered to have coronary 
heart disease (CHD). Multiple comorbidities 
were noted and reported as different disease 
entities, for example, the number of patients 
with diabetes mellitus, kidney disease, stroke 
and others was reported individually. Implicit 
review of the patients’ medical record was 
conducted to note adverse drug reactions, 
contraindications and statement about the 
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inefficacy of a drug which may indicate why 
the drug is changed or not prescribed or 
other acceptable rationale for non-adherence 
to guidelines.  
 
A total of 260 patients of the enrolled 325 
patients (20 per enrolled doctor) were 
followed-up to the 2nd visit. On the second 
visit, BP readings were noted and patients 
were categorized either as having controlled 
or uncontrolled hypertension based on the 
goals defined by CPG 2008 (Table 1). 
Prescriptions written on the 1st visit classified 
either as adherent or non-adherent to CPG 
2008 were then related to hypertension 
control status on the 2nd visit. 
 
Table 1: Malaysian Clinical Practice Guidelines 
(CPG 2008) recommended BP goals [3] 
 








Diabetes and/or CKD  
< 130/80 
Hypertension with 
proteinuria ≥ 1 g/24 h 
< 125/75 
CKD = chronic kidney disease 
 
Doctors’ were considered compliant to 
guidelines if they satisfied one of the 
following criteria:  
 
i. CPG 2008 recommended first line agents 
for the particular condition was prescribed 
to the patient. 
ii. CPG 2008 recommended first line agents 
having no contraindications to its use 
were prescribed to patients with multiple 
comorbidities. 
iii. CPG 2008 recommended first line agent 
for a particular condition was not 
prescribed because of adverse drug 
reactions caused by the recommended 
drug, contraindication to its use or the 





Data were analyzed by using Statistical 
Package for Social Sciences (version 16.0, 
SPSS Inc, Chicago, IL). Categorical data 
were reported as frequencies and 
percentages, and continuous data as mean ± 
SD. Chi-square and Fischers Exact tests 
were used to detect significance between 
categorical variables. P < 0.05 was 
considered statistically significant. When 
significant association was observed, the 
strength and direction of association was 
determined using Phi coefficient. Phi values 
from 0.000 to < 0.10, 0.10 to < 0.2, and 0.20 
to < 0.40 were considered as negligible, 
weak and moderate association, respectively 
[9]. A negative Phi value indicates negative 




This study was approved by the Ministry of 
Health Medical Research Ethics Committee 




Patients’ demographic and clinical 
characteristics 
 
Of the 260 established hypertensive patients 
with cardiovascular comorbidities included in 
the final analysis, 166 (63.8%) were males. 
Mean age of the patients was 62.3 + 10.0 
years, 156 (60%) had age < 65 years. The 
study sample was ethnically diverse and 
consisted of Chinese 111 (42.7 %), Malay 91 
(35 %), Indian 53 (20.4 %), and other 
ethnicities, 5 (1.9 %). Two hundred and nine 
(80.4 %) were non-smokers and 251 (96.5 %) 
were teetotalers. Only 23 (8.8 %) patients 
had a positive family history of cardiovascular 
disease. 
 
The number of comorbidities recorded were 
674. Only 31 (11.9 %) had a single 
comorbidity, while 97 (37.3 %), 87 (33.5 %), 
45 (17.3 %) had two, three and more than 
three  comorbidities,  respectively.  The most  
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Table 2: Gender and age-wise distribution of comorbidities 
 
Variable Gender, N (%) 
Male                    Female 
Age, N (%) 







































CHD 152 (91.6) 70 (74.5) 82 (78.8) 140 (89.7) 222 (32.9) 
HF 48 (28.9) 36 (38.3) 38 (36.5) 46 (29.5) 84 (12.46) 
LVH 7 (4.2) 5 (5.3) 5 (4.8) 7 (4.5) 12 (1.78) 
Dyslipidemia 98 (59.0) 45 (47.9) 52 (50.0) 91 (58.3) 143 (21.21) 
DM 82 (49.4) 42 (44.7) 51 (49.0) 73 (46.8) 124 (18.39) 
CKD 20 (12.0) 10 (10.6) 13 (12.5) 17 (10.9) 30 (4.45) 
Cerebrovascular 
disease 
13 (7.8) 13 (13.8) 20 (19.2) 6 (3.8) 26 (3.85) 
Asthma 10 (47.61) 11 (52.38) 6 (28.57) 15 (71.42) 21 (3.11) 
Gout 6  (75) 2 (25) 3 (37.5) 5 (62.5) 8 (1.18) 
PVD 1 (25) 3 (75) - 4 (100) 4 (0.59) 
CHD = coronary heart disease; CKD = chronic kidney disease; CVD = cardiovascular disease; DM = 
diabetes mellitus; LVH = left ventricular hypertrophy; PVD = peripheral vascular disease 
 
common comorbidity was coronary heart 
disease with 222 (32.9 %) having this 
condition, followed by dyslipidemia 143 (21.2 
%), diabetes mellitus 124 (18.4 %), heart 
failure 84 (12.5 %), chronic kidney disease 30 
(4.5 %), cerebrovascular disease 26 (3.9 %), 
asthma 21 (3.1 %), left ventricular 
hypertrophy 12 (1.8 %), gout 8 (1.2 %), and 
peripheral vascular disease 4 (0.6 %). 
Gender and age-wise distribution of 
comorbidities is as shown in Table 2.. 
 
Clinical practice guidelines adherence 
 
One hundred and ninety one patients (73.5 
%) received CPG (2008) compliant therapy. 
CPG adherence was found to have a 
statistically significant moderate negative 
association with LVH (Ф = -0.241, p < 0.01), 
and diabetes mellitus (Ф = -0.228, p < 0.01). 
No statistically significant association was 
found between CPG adherence and any 




One hundred and fifty four (59.2 %) patients 
were on goal BP on visit 2 as compared to 
one hundred and twenty one (46.5) on 1st 
visit. Hypertension control was found to have  
 
Table 3: Factors associated with clinical practice guidelines adherence 
 
Variable CPG adherence, N (%) 
Yes                       No 
P-value Effect size (Ф) 
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a Chi square test; b Fischer Exact test; Ф, Phi value; DM = diabetes mellitus; LVH = left ventricular 
hypertrophy 
Table 4: Factors associated with hypertension control 
 
Variable BP control, N (%) 
Yes                                 No 
P-value Effect size (Ф) 

































































a Chi Square test; b Fischer Exact test; Ф = Phi value;  ACEI = angiotensin converting enzyme inhibitors; 
CPG = clinical practice guidelines; DM = diabetes mellitus; LVH= left ventricular hypertrophy   
 
a statistically significant weak positive 
association with CPG compliance (Ф = 0.175, 
p < 0.01) and ACE inhibitors (Ф = 0.195, p < 
0.01), while statistically significant weak 
negative association with LVH (Ф = -0.153, p 
= 0.017), diabetes (Ф = -0.148, p = 0.017) 
and monotherapy (Ф = -0.168, p < 0.01). No 
statistically significant association was found 
between hypertension control and any other 




In our study we found an overall fair level of 
adherence to medication recommendations 
of CPG (2008). More than two third (73.5 %) 
of the total prescriptions written were in 
compliance with CPG 2008.  This finding is in 
contrast to some of the previous studies 
conducted elsewhere and Malaysia [11,12] 
which have reported poor adherence to 
guidelines, but is in compliance with some 
studies which have reported good adherence 
to guidelines [13,14]. This fair level of 
adherence to the hypertension guidelines 
might be due to the model proposed by Piette 
and Kerr [15].  
 
According to the model, patients with 
concurrent comorbidities of overlapping 
pathophysiological pathways and manage-
ment like hypertension and cardiovascular 
disease are more likely to receive guidelines 
adherent management. Similar guidelines 
recommended hypertension management 
was found to be significantly associated with 
patient total comorbidities, coronary artery 
disease, and history of myocardial infarction 
[16]. In the present study, CPG adherence 
was found to have negative association with 
diabetes mellitus and left ventricular 
hypertrophy. A similar report of doctors’ poor 
compliance to hypertension guidelines while 
treating hypertension in diabetic patients was 
shown by another study conducted in 
Malaysia, where only 18.3 % of the diabetic 
hypertensive patients were on guidelines 
recommended ACE inhibitors [12]. In our 
study the possible reason for poor adherence 
to guidelines while treating diabetic 
hypertensive patients might be the fact that 
the clinic is a specialist clinic focusing on 
treating cardiovascular disease. However, a 
large-scale study in various cardiology clinics 
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will be needed to confirm this. Another 
possible reason for poor adherence with 
hypertension guidelines in patients with left 
ventricular hypertrophy might be due to the 
fact that only a single antihypertensive class, 
Angiotensin receptor blocker, is 
recommended by CPG (2008) as first choice, 
compared to the wider range of 
antihypertensive classes recommended for 
coronary heart disease and heart failure. In 
the present study, 7 (53.8 %) patients with 
left ventricular hypertrophy were receiving 
diuretics as compared to 4 (33.3 %) patients 
who were receiving guideline recommended 
angiotensin receptor blockers. 
 
In our study, majority of patients (59.2 %) 
were at goal BP on the 2nd visit, a rate that 
was more than twice that of the Malaysian 
national bench mark of hypertension control 
(26.8 %) [7]. Hypertension control in our 
study was much higher than a recent multi-
centre study conducted in Malaysia, in which 
48.5 % of the patients had achieved BP 
control [17]. Reasons for this better 
hypertension control, compared to other 
studies conducted in Malaysia, might be the 
aggressive pharmacotherapy and doctors’ 
greater compliance to hypertension 
guidelines. Similar better hypertension control 
in patients suffering from cardiovascular 
disease is reported by a study conducted 
elsewhere [18]. Better control of hypertension 
in patients suffering from cardiovascular 
disease might be due the fact that physicians 
seeing the patients with a critical disease pay 
more attention [19], and physicians and 
patients become more aware of the needs to 
maintain BP goal levels, once organ and 
vascular complications present [18].  
 
Hypertension control had statistically 
significant positive association with CPG 
adherence and ACE inhibitors. Majority of the 
previous studies which have evaluated 
physicians’ adherence to hypertension 
guidelines have not related practices to 
hypertension control. This finding was in 
compliance with the study conducted in 
Malaysia where adherence to recommended 
practices resulted in better hypertension 
control [4]. The efficacy of ACE inhibitors in 
patients at high and lower risk of 
cardiovascular disease like those with 
coronary heart disease, congestive heart 
failure, cerebrovascular disease, chronic 
kidney disease, and diabetes has been 
demonstrated by several large clinical trials 
[20, 21]. Due to this reason ACE inhibitors 
are recommended by guidelines as choice of 
therapy in these conditions [3]. A majority of 
patients in our study were suffering from 
these conditions, so better control of 
hypertension in patients receiving ACEI was 
in compliance with guidelines recommend-
dations and findings of the above stated 
trials. 
 
Hypertension control was found to have 
statistically significant negative association 
with diabetes, left ventricular hypertrophy, 
and patients on monotherapy. Similar poor 
hypertension control in diabetic patients was 
reported by a study conducted in Malaysia, 
where only 3.1% diabetic hypertensive 
patients achieved the target BP of less than 
130/80 mm Hg [12] . One possible reason for 
the negative association could be the more 
stringent BP goals (hypertension with 
diabetes mellitus and/or CKD <130/80 mm 
Hg, and with proteinuria > 1 g/24 h < 125/75 
mm Hg) which are difficult to achieve in 
clinical settings [22]. Besides, this statistically 
significant negative association between 
CPG adherence and diabetes might have 
adversely affected hypertension control in 
diabetic patients, because of significant 
positive association between CPG adherence 
and hypertension control in our study. The 
negative association found between 
hypertension control and LVH seems to be a 
consequence of noncompliance to 
hypertension guidelines. This finding further 
strengthens the concept that adherence to 
hypertension guidelines leads to better 
hypertension control. The poor control of 
hypertension in patients receiving 
monotherapy as compared to polytherapy 
seems logical, because most of the patients 
were suffering from multiple comorbidities 
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and were in an age group in which BP control 
is normally achieved by using multiple 
antihypertensive drugs [3,23].  
Limitations of this study 
 
Conducting this study in a single site is the 
major limitation associated with our study. 
We evaluated prescribing practices only, and 
not the other components of hypertension 
management such as screening, life style 
interventions, pharmacotherapy and 
continued follow up. We followed patients for 
only one visit, hypertension is a chronic 
disease and needs a long observation period 
to decide whether the hypertension is 
controlled or not. However, to overcome this 
limitation we enrolled established 
hypertensive patients to make sure that BP 
reading noted on the 1st visit was the 
representative BP of the patient. The non-
availability of certain anthropometric 
measurements like body weight, Body Mass 
Index (BMI), etc, and statements about 
patients’ compliance to pharmacotherapy are 





Overall prescribing practices were in fair 
compliance with guidelines, but still have a 
room for further improvement Compliance to 
CPG 2008 resulted in better hypertension 
control in patients suffering from 
cardiovascular comorbidities. Poor 
adherence to guidelines in patients suffering 
from diabetes mellitus and LVH are the areas 
which need further probing and focus in the 
future. Different strategies like continuous 
medical education, seminars, reminder tools 
and the availability of clinical pharmacist to 
participate in collaborative practices and 
motivating patients to participate in BP goal 
achievement could increase guidelines 
adherence and hypertension control. 
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